Knight Jeff E. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Crinetics (CRNX) COO Jeff Knight Sells Shares
What Happened
Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals (CRNX), sold a total of 9,911 shares on March 16, 2026 in two open-market transactions: 5,950 shares at a VWAP of $37.11 for $220,805, and 3,961 shares at a VWAP of $37.77 for $149,607 — total proceeds ≈ $370,412. The sales were made to satisfy tax-withholding obligations arising from vested restricted stock units.
Key Details
- Transaction dates: March 16, 2026 (reported on Form 4 filed March 18, 2026). Filing appears timely (within the required reporting window).
- Lots/prices: 5,950 shares @ VWAP $37.11 (range $36.42–$37.38); 3,961 shares @ VWAP $37.77 (range $37.42–$38.23).
- Total shares sold: 9,911; total proceeds ≈ $370,412.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Footnotes: Sales were to cover tax withholding on RSU vestings (grants from 2022–2025) and were effected by a broker under a Rule 10b5‑1 trading plan.
- Transaction code: S = Sale; tax-withholding code/footnote indicated (F1/F2/F3).
Context
These were routine sell-to-cover transactions tied to RSU vesting and executed under a pre-established 10b5‑1 plan — common administrative actions that do not necessarily indicate a change in the insider’s view of the company. For more detail (exact post-transaction holdings or lot-level data), see the full Form 4 filing (Accession 0001628280-26-019503).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-16$37.11/sh−5,950$220,805→ 115,979 total - Sale
Common Stock
[F1][F3]2026-03-16$37.77/sh−3,961$149,607→ 112,018 total
Footnotes (3)
- [F1]Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F3]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.